Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.
about
Characterizing autism spectrum disorders by key biochemical pathways.Dysregulation and restoration of translational homeostasis in fragile X syndromeThe neurology of mTORLearning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and BackReview of targeted treatments in fragile X syndromeFragile X mental retardation protein: A paradigm for translational control by RNA-binding proteinsPax6-dependent cortical glutamatergic neuronal differentiation regulates autism-like behavior in prenatally valproic acid-exposed rat offspringIn vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndromeFrom FMRP function to potential therapies for fragile X syndrome.Modeling fragile X syndrome in the Fmr1 knockout mouseA protocol for evaluation of Rett Syndrome symptom improvement by metabolic modulators in Mecp2-mutant mice.A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome.The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.Spaced training rescues memory and ERK1/2 signaling in fragile X syndrome model mice.Impaired cognitive discrimination and discoordination of coupled theta-gamma oscillations in Fmr1 knockout mice.Data gaps limit the translational potential of preclinical research.β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X.Cholesterol in the Pathogenesis of Alzheimer's, Parkinson's Diseases and Autism: Link to Synaptic DysfunctionDelta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis.Chd8 Mutation Leads to Autistic-like Behaviors and Impaired Striatal CircuitsFragile X targeted pharmacotherapy: lessons learned and future directions.Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and AutismExtinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice.A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs.Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.Fragile X mental retardation protein: from autism to neurodegenerative disease.Homer protein-metabotropic glutamate receptor binding regulates endocannabinoid signaling and affects hyperexcitability in a mouse model of fragile X syndrome.Quantitative profiling of brain lipid raft proteome in a mouse model of fragile X syndromeFmr1 KO and fenobam treatment differentially impact distinct synapse populations of mouse neocortex.Convergence of Hippocampal Pathophysiology in Syngap+/- and Fmr1-/y Mice.Identification of a male with fragile X syndrome through newborn screeningElevated CaMKIIα and Hyperphosphorylation of Homer Mediate Circuit Dysfunction in a Fragile X Syndrome Mouse Model.Layer specific and general requirements for ERK/MAPK signaling in the developing neocortexTargeting Translation Control with p70 S6 Kinase 1 Inhibitors to Reverse Phenotypes in Fragile X Syndrome Mice.Agonist-dependent signaling by group I metabotropic glutamate receptors is regulated by association with lipid domainsAPP Causes Hyperexcitability in Fragile X Mice.Lipid rafts: a signaling platform linking cholesterol metabolism to synaptic deficits in autism spectrum disorders.
P2860
Q26781645-C7D3BA60-E518-4DBA-898C-3C5BD00E0CA3Q26782616-A5743931-69B1-48F9-B733-C25730AF66EAQ26824286-72E931AC-ACC0-4C7D-80A6-21199CCF35F9Q26866506-08AA24A8-E4DA-48BB-9676-2ECA5B197AF3Q27023257-5B1F1823-EC1B-49BF-BBB9-38E938CDF40FQ27337360-7B5B3BD8-8247-4F5E-9926-1664C33C0E30Q28077180-F50F8F30-6C22-45CF-9D27-9C9987D5334DQ28086823-5137D06B-3C4C-41DA-96BB-7B39B1E51119Q28941206-54212CF6-D85C-49E2-BB58-59B4BF11D86BQ30406616-6B90947B-3B2B-4BF6-9239-A9F6D647DFE5Q30410502-7D900ED7-1DA7-4A2E-AA3C-56A1BB8F1DA0Q30420595-9C522430-EEAE-432A-B98A-2B0EB8E7758BQ30422702-78D02E57-2F73-4C9E-B57C-D864586E5D37Q30442429-64350A52-B03F-434C-83CE-E94943B620FBQ30576758-D13CBC18-6362-4644-BE50-13BB5C805B3CQ30603928-E7285288-5C0D-4C2E-81DF-56B63EAE17C5Q30713841-945968A0-DFC5-4535-8EDD-258444768AF9Q31035567-16DD4012-C1ED-4301-A093-6BC9D824DE8CQ33562835-AC1D677C-59D1-435C-BF68-0120E0DC9061Q33607803-0164228E-A3B5-47C2-B9C8-7ABF6BBA28A2Q33651529-45FC346B-24EC-4DA3-8836-953DFAFDC4BBQ33756508-A33A0AD6-DD0F-4BF8-AA8C-77E4127C0E58Q33785983-E5E79C57-E72C-45DE-90D6-C4E133B85A31Q33877423-6D387E1B-78F8-4C37-8C35-C99B5F67EBE7Q34276734-D0C79B3E-9A5D-4F2A-A580-636571921902Q34392818-2DC5B28B-1BC8-4B57-A7B6-0CF24BBE5160Q34871401-743AA7FA-F92D-40E9-9E75-38DC44FDC205Q34959355-917F4793-7D88-409D-BCC9-42E8FE6AB572Q35077291-463B15B5-3533-49CD-97B9-72FDCBA90D6CQ35142914-873D3311-253B-4F6B-864C-B096A01FAEFCQ35302189-A713873C-3F25-41BD-BB7A-78091E6EE414Q35776690-D53CCCD5-F595-45D2-92AD-95B3A2F7B977Q36272528-D7F9D20B-839F-4703-9955-BD2DCF35EF1FQ36322068-DB7DBDD0-B5AA-40E5-A872-AA13465D8188Q36387172-9655E5DA-58F6-4158-AE9C-8FB73065C853Q36594223-FE2AC0D3-E3E2-4638-B70D-BDDA81505FF1Q37006293-A77D2D9A-BFC0-4FF8-85B7-B58F94081620Q37272208-FA9B939C-2520-4F0A-BCA0-EF9F30B01F3AQ37504141-8D5209AE-95E8-41D1-A806-36696C7CF3DCQ37681389-10DDB898-3117-4BC4-A084-3292817F1CF5
P2860
Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Lovastatin corrects excess pro ...... e model of fragile X syndrome.
@ast
Lovastatin corrects excess pro ...... e model of fragile X syndrome.
@en
type
label
Lovastatin corrects excess pro ...... e model of fragile X syndrome.
@ast
Lovastatin corrects excess pro ...... e model of fragile X syndrome.
@en
prefLabel
Lovastatin corrects excess pro ...... e model of fragile X syndrome.
@ast
Lovastatin corrects excess pro ...... e model of fragile X syndrome.
@en
P2093
P2860
P50
P1433
P1476
Lovastatin corrects excess pro ...... e model of fragile X syndrome.
@en
P2093
Mark F Bear
Michael Sidorov
Robert K S Wong
Shih-Chieh Chuang
P2860
P304
P356
10.1016/J.NEURON.2012.01.034
P407
P577
2013-01-01T00:00:00Z